Headlines about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive on Wednesday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.1540374859367 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Brokerages Anticipate Syros Pharmaceuticals (SYRS) to Post -$0.34 Earnings Per Share (americanbankingnews.com)
- Q2 2018 Earnings Forecast for Syros Pharmaceuticals Inc (SYRS) Issued By Wedbush (americanbankingnews.com)
- Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting (finance.yahoo.com)
- Syros Pharmaceuticals Inc (SYRS) to Post Q1 2018 Earnings of ($0.17) Per Share, Oppenheimer Forecasts (americanbankingnews.com)
Several research firms have recently issued reports on SYRS. HC Wainwright reissued a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday, March 14th. BidaskClub raised shares of Syros Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 1st. Oppenheimer reissued a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research note on Thursday, December 7th. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Friday, January 5th. Finally, Wedbush reissued an “outperform” rating and set a $13.00 target price (up from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Hold” and an average price target of $21.13.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.01). equities research analysts expect that Syros Pharmaceuticals will post -2.16 EPS for the current fiscal year.
In related news, Director Srinivas Akkaraju purchased 209,424 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were purchased at an average cost of $9.55 per share, with a total value of $1,999,999.20. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 33.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Syros Pharmaceuticals (SYRS) Stock Price” was reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/21/syros-pharmaceuticals-syrs-receiving-somewhat-positive-media-coverage-report-shows/1923628.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.